MEGAN CALAMUSA: Open Payments
NPI 1578061065 · CHARLOTTE, NC. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,292 in 27 payments from 7 companies in 2025. Trend: 2023 $135 · 2024 $500 · 2025 $3,292
Consulting: $1,500Travel & lodging: $1,028Food & beverage: $765
| Company | Payments | Amount |
|---|---|---|
| Daiichi Sankyo Inc. | 15 | $2,793 |
| Iovance Biotherapeutics, Inc. | 2 | $152 |
| AstraZeneca Pharmaceuticals LP | 2 | $152 |
| Janssen Biotech, Inc. | 5 | $131 |
| Merck Sharp & Dohme LLC | 1 | $23 |
| Immunocore Limited | 1 | $22 |
| Novartis Pharmaceuticals Corporation | 1 | $20 |
Products named: DATROWAY, Amtagvi, TAGRISSO, Enhertu, ERLEADA, RYBREVANT, KEYTRUDA QLEX, KIMMTRAK.
Industry payments across NC — which companies pay providers there.
